LoVo Transfection Reagent (Colon Adenocarcinoma)


Kit Size VolumePricePay with CC, PO, or PaypalAdd to Cart
0.5 ml (Catalog #6840)$390.00
1.5 ml (Catalog #6841)$775.00
1.5 ml CRISPR (Catalog #2167)$775.00
8.0 ml (Catalog #7057)$2,025.00
SKU: LOVO Category:


Purchase Orders: Click “Add to Cart” button to order, then email PO to orders@altogen.com.

Product Availability: In Stock.

Transfection Reagent for LoVo Cells (Colon Adenocarcinoma Cells, CCL-229)

  • Two component formulation enhances lipid mediated transfection efficiency
  • Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
  • Reproducible transfection results
  • Works well for standard reverse transfection and high-throughput applications
  • Download in vitro LoVo transfection protocol: [PDF]
  • Download LoVo CRISPR/Cas9 transfection protocol: [PDF]
  • Download PowerPoint presentation for LoVo cells transfection kit: [PPT]
  • UPC/GTIN/EAN: 860002089787
  • Brand: ALTOGEN®, developed and manufactured by Altogen Biosystems

Transfection Efficiency:

Reagent exhibits at least 94% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.

Product Description:

Optimized transfection kit for high transfection efficiency of LoVo cells, a human colon cancer cell line. Used in molecular biology to facilitate the introduction of foreign nucleic acids (DNA and RNA) into LoVo cells. Compatible with DNA and RNA transfection.

Transfection Protocol and SDS:

Download Altogen Biosystems LoVo Transfection Protocol: [PDF]

Download SDS: [PDF]

LoVo Cell Line:

Colorectal cancer is the third most commonly detected cancer in the United States, reportedly accounting for nearly 50,000 fatalities annually, as per the American Cancer Society (ACS). The LoVo epithelial cell line was isolated in 1971 from a metastatic tumor of a 56-year-old Caucasian male with colorectal adenocarcinoma. LoVo cells express multiple oncogenes, including N-ras, H-ras, Myb, c-myc, K-ras, sis and fos genes. Also, CC-3 and CC-4 tumor-specific nuclear matrix proteins are expressed. However, the cells are negative for expression of colon antigen 3 and CSAp (CSAp-). The LoVo cell line presents an aneuploid karyotype with a modal number of 49 and a doubling time of approximately 37 hours. A broad range of LoVo cells shows an extra B chromosome as well as altered A2. The LoVo cell line is a suitable host for studying various types of colon cancer. Altogen Biosystems provides highly efficient transfection reagent kits for the LoVo cell line.

LOVO cells are a type of human colon cancer cell line that was originally derived from a primary tumor in a patient with colorectal adenocarcinoma. These cells have been widely used as a model system for studying various aspects of colorectal cancer biology, including the molecular mechanisms underlying tumor development and progression, and the identification of potential therapeutic targets for the treatment of colorectal cancer. LOVO cells have several properties that make them useful for research. Firstly, they are relatively easy to culture in the laboratory and can be grown in large quantities. Secondly, they express markers of colorectal cancer, such as carcinoembryonic antigen (CEA) and mucin-1 (MUC-1), and exhibit several features characteristic of colorectal cancer, including uncontrolled proliferation, invasion, and metastasis. Thirdly, they respond to various stimuli, such as growth factors and cytokines, making them a useful model system for studying the effects of these factors on colorectal cancer cell growth and survival. Research using LOVO cells has contributed significantly to our understanding of colorectal cancer biology. For example, LOVO cells have been used to study the role of various signaling pathways, such as the Wnt/β-catenin and PI3K/Akt/mTOR pathways, in the development and progression of colorectal cancer. Additionally, LOVO cells have been used to screen for potential anticancer agents, including chemotherapy drugs and targeted therapies. Furthermore, LOVO cells have been used to study the mechanisms underlying drug resistance in colorectal cancer. Studies have shown that resistance to chemotherapy drugs such as 5-fluorouracil (5-FU) and oxaliplatin can arise due to alterations in drug metabolism, DNA damage repair mechanisms, and drug efflux pumps. Understanding the mechanisms of drug resistance in LOVO cells has led to the development of combination therapies and targeted therapies that can overcome drug resistance in colorectal cancer.


KRAS 3845 37 12 25398281 25398281 Missense_Mutation SNP C T
FBXW7 55294 37 4 153247289 153247289 Missense_Mutation SNP G A
GRM7 2917 37 3 7620310 7620310 Nonsense_Mutation SNP C T
PIK3CB 5291 37 3 138374293 138374293 Missense_Mutation SNP C T
DCDC1 341019 37 11 30953328 30953328 De_novo_Start_OutOfFrame SNP G A
TRPV3 162514 37 17 3431412 3431412 Silent SNP C T
KIAA1644 85352 37 22 44681447 44681447 Missense_Mutation SNP G A
DTX3L 151636 37 3 122284753 122284753 Missense_Mutation SNP G A
LIX1 167410 37 5 96430694 96430694 Missense_Mutation SNP G A
ANKHD1 54882 37 5 139886500 139886500 Silent SNP G A
SLC17A2 10246 37 6 25921500 25921500 Silent SNP C A
HIST1H4G 8369 37 6 26247163 26247163 Missense_Mutation SNP C T
CHRNA2 1135 37 8 27320707 27320707 Missense_Mutation SNP T A


LoVo Cells Transfection Kit

Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into LoVo cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by qRT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).


Figure 2. Protein expression of Lamin A in LoVo cells. DNA plasmid expressing Lamin A or siRNA targeting Lamin A were transfected into LoVo cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.

Selected LoVo transfection reagent citations:

  • Carcinogenesis. 2014. A mechanistic study of the proapoptotic effect of tolfenamic acid … Jeong et al [PDF]
  • Diabetologia. 2012 55(7):2069-79. The p47phox- and NADPH oxidase organiser 1 … Youn et al [PDF]

Altogen Biosystems transfection and electroporation products for life sciences and cancer research. Company developed two types of in vivo delivery kits for animal research: Tissue-targeted reagents (delivery to liver, pancreas, and kidney tissues), and broad range in vivo delivery reagents (PEG-Liposome, Nanoparticle-based, Lipid-based, and Polymer-based kits).  Advanced formulation of reagents and optimized transfection protocols provide efficient intracellular delivery of proteins, DNA, mRNA, shRNA, siRNA, and other negatively charged molecules in vitro and in vivo. Read more about transfection technology at Altogen’s Transfection Resource. Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (90+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).

LoVo Transfection Reagent

Volume Options:

  • 0.5 ml (Catalog #6840)
  • 1.5 ml (Catalog #6841)
  • 1.5 ml CRISPR (Catalog #2167)
  • 8.0 ml (Catalog #7057)

Purchase Orders: Click “Add to Cart” button to order, then email PO to orders@altogen.com.

Product Availability: In Stock.

Additional information

Weight 1 lbs
Dimensions 4 × 3 × 0.2 in
Kit Size (Volume)

0.5 ml (Catalog #6840), 1.5 ml (Catalog #6841), 1.5 ml CRISPR (Catalog #2167), 8.0 ml (Catalog #7057)